Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.

Mostrar otras versiones (2)

Detalles Bibliográficos
Autores principales:	Druce, M, Chung, T, Grozinsky-Glasberg, S, Gross, D, Grossman, AB
Formato:	Journal article
Lenguaje:	English
Publicado:	2012

Ejemplares similares

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
por: Druce, M, et al.
Publicado: (2012)

Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma
por: Druce, M, et al.
Publicado: (2010)

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
por: Grozinsky-Glasberg, S, et al.
Publicado: (2010)

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
por: Grozinsky-Glasberg, S, et al.
Publicado: (2009)

In-situ analysis of calcitonin and CGRP expression in medullary thyroid carcinoma.
por: Boultwood, J, et al.
Publicado: (1990)

Everolimus therapy for progressive adrenocortical cancer
por: Fraenkel, M, et al.
Publicado: (2013)

Everolimus therapy for progressive adrenocortical cancer.
por: Fraenkel, M, et al.
Publicado: (2013)

Medullary thyroid cancer: molecular biology and novel molecular therapies.
por: Cakir, M, et al.
Publicado: (2009)

Medullary thyroid carcinoma and duodenal calcitonin-secreting neuroendocrine tumour: more than coincidence?
por: Huguet, I, et al.
Publicado: (2013)

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
por: Chan, H, et al.
Publicado: (2010)

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
por: Van Allen, Eliezer M., et al.
Publicado: (2017)

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
por: Druce, MR, et al.
Publicado: (2009)

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
por: Mukherjee, J, et al.
Publicado: (2001)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
por: Grozinsky-Glasberg, S, et al.
Publicado: (2011)

Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum
por: Zhou, Jingan, et al.
Publicado: (2021)

Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum
por: Zhou, Jingan, et al.
Publicado: (2022)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
por: Gupta, P, et al.
Publicado: (2014)

EVEROLIMUS PLUS OCTREOTIDE LAR IN PATIENTS WITH LUNG CARCINOIDS
por: Granberg, D, et al.
Publicado: (2014)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
por: Sen Gupta, P, et al.
Publicado: (2014)

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply
por: Jr, W, et al.
Publicado: (2012)

IGF2-induced hypoglycemia unresponsive to everolimus.
por: Korevaar, T, et al.
Publicado: (2014)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
por: Grozinsky-Glasberg, S, et al.
Publicado: (2008)

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
por: Wells, SA, et al.
Publicado: (2012)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
por: Grozinsky-Glasberg, S, et al.
Publicado: (2008)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
por: Den Gupta, P, et al.
Publicado: (2011)

Metastatic follicular thyroid carcinoma to the mandible: a case report
por: Zain, R.B., et al.
Publicado: (2009)

Medullary carcinoma of the breast : role of contrastenhanced MRI in the diagnosis of multiple breast lesions.
por: Abdul Rashid, Saiful Nizam, et al.
Publicado: (2009)

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer
por: McFadden, David Glenn, et al.
Publicado: (2014)

Dandy-Walker malformation, papillary thyroid carcinoma, and SDHD-associated paraganglioma syndrome.
por: Huguet, I, et al.
Publicado: (2013)

Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study.
por: Rinaldi, S, et al.
Publicado: (2014)

Metastatic thyroid carcinoma presenting with spinal cord compression.
por: Hassan, H. A., et al.
Publicado: (2010)

Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
por: Gueorguiev, M, et al.
Publicado: (2010)

Cancer in the thyroid is not always thyroid cancer.
por: Akester, K, et al.
Publicado: (2003)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
por: Grozinsky-Glasberg, S, et al.
Publicado: (2008)

Combination of everolimus with sorafenib for solid renal tumors in Tsc2+/- mice is duperior to everolimus alone
por: Yang, J, et al.
Publicado: (2017)

Everolimus for renal angiomyolipoma in tuberous sclerosis.
por: Sooriakumaran, P, et al.
Publicado: (2013)

Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.
por: Kaltsas, G, et al.
Publicado: (2014)

An unusual first presentation of hypopharyngeal carcinoma as thyroid abscess: Case report of a diagnostic challenge
por: Heng Yao Tan, et al.
Publicado: (2021)

Effect of Everolimus plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours - Analysis From RADIANT-2
por: Fazio, N, et al.
Publicado: (2011)

MicroRNA profiling of papillary thyroid carcinoma cell lines
por: Smyth, P, et al.
Publicado: (2007)